Collegium Pharmaceutical Hits New 52-Week Low at $27.11

Collegium Pharmaceutical, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 27.11 as of August 10, 2026. This decline marks a significant downturn for the company, which has experienced a 1-year performance drop of 18.34%, contrasting sharply with the S&P 500's gain of 21.34% during the same period. Despite the recent price drop, Collegium maintains a market capitalization of USD 1,058 million. The company's price-to-earnings (P/E) ratio stands at 14.00, indicating its current valuation relative to earnings. However, the firm faces challenges in servicing its debt, reflected in a poor EBIT to Interest ratio of 1.55. On a positive note, Collegium has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 20.28% and operating profit rising by 26.76%. The company has also reported a return on equity of 25.00%, showcasing its efficiency in generating profits from shareholders' equity. However, recent financial results have shown a decline, with profits falling by 15.8% over the past year.